This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
From Provider to Patient: Opportunities and Dialogue for Appropriate Pain Management (Pharmacy Credit)

From Provider to Patient: Opportunities and Dialogue for Appropriate Pain Management (Pharmacy Credit)

Format

Webcast

Time to Complete

1 hour

Released

May 22, 2017

Expires

May 22, 2018
Add to Queue


Maximum Credits

1.00 / CPE for Pharmacists (0.10 CEUs)

Note About Credits

A separate version of this activity offers 1.00 AMA PRA Category 1 Credit(s)TM. If you would like to complete this activity for AMA PRA Category 1 Credit(s)TM, please click here.

Accredited Provider



Sponsored by the Academy for Continued Healthcare Learning

Commercial Supporter

This activity is supported by educational funding provided by Teva Pharmaceuticals.

Program Description

Nearly 100 million people in the United States, or roughly one-third of the population, experience some form of chronic pain. Meanwhile, prescription opiate abuse and addiction have reached epidemic proportions in the United States, including the widespread illegal diversion of prescription opioids for street use, which in turn can increase the rates of abuse of illegal narcotics. Some clinicians have also prescribed opioids without adequate training surrounding their abuse potential. Many primary-care providers have recently become reluctant to prescribe opioid pain relievers in the context of current public health concerns surrounding addiction, which leads to some chronic pain patients now going without any appropriate treatment. The development of new clinical practice guidelines from the Centers for Disease Control and Prevention (CDC) regarding prescription opioids presents both a challenge and an opportunity for clinicians to offer safer and more effective management of pain. Meanwhile, the development of new opioid therapeutic options that employ abuse-deterrent technology may help reduce the illegal diversion of prescription opiates for street use.

This activity educates physicians, pharmacists, and other allied-health personnel on the latest CDC guidelines surrounding prescription opioids as well as the latest epidemiological data surrounding addiction management and treatment. Multiple expert physicians trained in pain management as well as addiction management will discuss current best practices in both disciplines, while academic pharmacists will explain mechanisms of action, potential side effects, and regulatory issues surrounding prescription opioid medications, including novel therapies that employ abuse-deterrent technology.

Intended Audience

This educational activity is designed for clinicians involved in the care and treatment of patients with chronic pain, as well as pain patients who may be at risk for substance abuse.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • List patient characteristics that should be analyzed by pharmacists when validating and dispensing opioid prescriptions for chronic non-cancer pain
  • Discuss how the 2016 CDC guidelines on prescription opiates impact opioid prescribing practices, prescription monitoring and reporting, and patient access
  • Outline the different types of opioid formulations, their mechanisms of action, and how they serve as abuse deterrents for patients on chronic opioid therapy
  • Describe how pharmacists can improve communication strategies with both physicians and pharmacists to improve outcomes in patients receiving chronic opioid therapy

Conflict Of Interest Disclosure Policy

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.

Faculty

Ruixuan Jiang, PharmD
PhD Student
University of Illinois at Chicago
College of Pharmacy
Department of Pharmacy Systems, Outcomes, and Policy
Chicago, IL

Dr. Jiang has nothing to disclose.

Todd Lee, PharmD, PhD
Professor
University of Illinois at Chicago
College of Pharmacy
Department of Pharmacy Systems, Outcomes, and Policy
Chicago, IL

Dr. Lee has nothing to disclose.

Michael Phillip Sprintz, DO
Founder and CEO
Sprintz Center for Pain and Dependency
The Woodlands, TX

Dr. Sprintz discloses the following:
Cellarian Health, LLC: CEO
Daichii Sankyo, Inc.: Consultant
Endo Pharmaceuticals: Chronic Pain Advisory Board – honorarium recipient/consultant

Forest Tennant, MD, MPH, DrPH
Pain Management Specialist
West Covina, CA

Dr. Tennant has nothing to disclose.

Moderated by:
Barbara Lewis, BA

Healthcare News Reporter and Anchor
Inside Indiana Business
Sound Medicine
, WFYI Public Radio/Indiana University School of Medicine

Staff Disclosures

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Credit

1.00

Type

CE for Pharmacists

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation Statement

This activity has been approved for 1.00 contact hour.

ACPE Universal Activity Number: 0396-0000-17-007-H01-P
Activity Type: Knowledge

Release Date: May 17, 2017
Expiration Date: May 17, 2018

Note: CPE credit will be submitted to CPE Monitor® on the first day of each month.

Disclosure of Unlabeled Use

This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support, as well as the ACPE Accreditation Standards for Continuing Pharmacy Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

Instructions

This activity will take 60 minutes to complete. To obtain credit, a score of 60% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact:
Katie Hacias
Associate Program Director
khacias@achlcme.org

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue